420 related articles for article (PubMed ID: 28386132)
1. Adaptive immune responses to booster vaccination against yellow fever virus are much reduced compared to those after primary vaccination.
Kongsgaard M; Bassi MR; Rasmussen M; Skjødt K; Thybo S; Gabriel M; Hansen MB; Christensen JP; Thomsen AR; Buus S; Stryhn A
Sci Rep; 2017 Apr; 7(1):662. PubMed ID: 28386132
[TBL] [Abstract][Full Text] [Related]
2. Immune activation alters cellular and humoral responses to yellow fever 17D vaccine.
Muyanja E; Ssemaganda A; Ngauv P; Cubas R; Perrin H; Srinivasan D; Canderan G; Lawson B; Kopycinski J; Graham AS; Rowe DK; Smith MJ; Isern S; Michael S; Silvestri G; Vanderford TH; Castro E; Pantaleo G; Singer J; Gillmour J; Kiwanuka N; Nanvubya A; Schmidt C; Birungi J; Cox J; Haddad EK; Kaleebu P; Fast P; Sekaly RP; Trautmann L; Gaucher D
J Clin Invest; 2014 Jul; 124(7):3147-58. PubMed ID: 24911151
[TBL] [Abstract][Full Text] [Related]
3. CD8+ T cells complement antibodies in protecting against yellow fever virus.
Bassi MR; Kongsgaard M; Steffensen MA; Fenger C; Rasmussen M; Skjødt K; Finsen B; Stryhn A; Buus S; Christensen JP; Thomsen AR
J Immunol; 2015 Feb; 194(3):1141-53. PubMed ID: 25539816
[TBL] [Abstract][Full Text] [Related]
4. Booster dose after 10 years is recommended following 17DD-YF primary vaccination.
Campi-Azevedo AC; Costa-Pereira C; Antonelli LR; Fonseca CT; Teixeira-Carvalho A; Villela-Rezende G; Santos RA; Batista MA; Campos FM; Pacheco-Porto L; Melo Júnior OA; Hossell DM; Coelho-dos-Reis JG; Peruhype-Magalhães V; Costa-Silva MF; de Oliveira JG; Farias RH; Noronha TG; Lemos JA; von Doellinger Vdos R; Simões M; de Souza MM; Malaquias LC; Persi HR; Pereira JM; Martins JA; Dornelas-Ribeiro M; Vinhas Ade A; Alves TR; Maia Mde L; Freire Mda S; Martins Rde M; Homma A; Romano AP; Domingues CM; Tauil PL; Vasconcelos PF; Rios M; Caldas IR; Camacho LA; Martins-Filho OA
Hum Vaccin Immunother; 2016; 12(2):491-502. PubMed ID: 26360663
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice.
Bassi MR; Larsen MA; Kongsgaard M; Rasmussen M; Buus S; Stryhn A; Thomsen AR; Christensen JP
PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004464. PubMed ID: 26886513
[TBL] [Abstract][Full Text] [Related]
6. 17DD Yellow Fever Revaccination and Heightened Long-Term Immunity in Populations of Disease-Endemic Areas, Brazil.
Campi-Azevedo AC; Peruhype-Magalhāes V; Coelho-Dos-Reis JG; Antonelli LR; Costa-Pereira C; Speziali E; Reis LR; Lemos JA; Ribeiro JGL; Bastos Camacho LA; de Sousa Maia ML; Barbosa de Lima SM; Simões M; de Menezes Martins R; Homma A; Cota Malaquias LC; Tauil PL; Costa Vasconcelos PF; Martins Romano AP; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA;
Emerg Infect Dis; 2019 Aug; 25(8):1511-1521. PubMed ID: 31298654
[TBL] [Abstract][Full Text] [Related]
7. Minimal immune response to booster vaccination against Yellow Fever associated with pre-existing antibodies.
Bovay A; Nassiri S; Maby-El Hajjami H; Marcos Mondéjar P; Akondy RS; Ahmed R; Lawson B; Speiser DE; Fuertes Marraco SA
Vaccine; 2020 Feb; 38(9):2172-2182. PubMed ID: 32008879
[TBL] [Abstract][Full Text] [Related]
8. Early IFN-gamma production after YF 17D vaccine virus immunization in mice and its association with adaptive immune responses.
Neves PC; Santos JR; Tubarão LN; Bonaldo MC; Galler R
PLoS One; 2013; 8(12):e81953. PubMed ID: 24324734
[TBL] [Abstract][Full Text] [Related]
9. Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children.
Campi-Azevedo AC; Reis LR; Peruhype-Magalhães V; Coelho-Dos-Reis JG; Antonelli LR; Fonseca CT; Costa-Pereira C; Souza-Fagundes EM; da Costa-Rocha IA; Mambrini JVM; Lemos JAC; Ribeiro JGL; Caldas IR; Camacho LAB; Maia MLS; de Noronha TG; de Lima SMB; Simões M; Freire MDS; Martins RM; Homma A; Tauil PL; Vasconcelos PFC; Romano APM; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA
Front Immunol; 2019; 10():2192. PubMed ID: 31616412
[TBL] [Abstract][Full Text] [Related]
10. Lymphocyte subset analyses in healthy adults vaccinated with yellow fever 17DD virus.
Santos AP; Bertho AL; Dias DC; Santos JR; Marcovistz R
Mem Inst Oswaldo Cruz; 2005 May; 100(3):331-7. PubMed ID: 16113878
[TBL] [Abstract][Full Text] [Related]
11. The early cellular signatures of protective immunity induced by live viral vaccination.
Kohler S; Bethke N; Böthe M; Sommerick S; Frentsch M; Romagnani C; Niedrig M; Thiel A
Eur J Immunol; 2012 Sep; 42(9):2363-73. PubMed ID: 22733156
[TBL] [Abstract][Full Text] [Related]
12. Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers.
Lindsey NP; Horiuchi KA; Fulton C; Panella AJ; Kosoy OI; Velez JO; Krow-Lucal ER; Fischer M; Staples JE
J Travel Med; 2018 Jan; 25(1):. PubMed ID: 30346562
[TBL] [Abstract][Full Text] [Related]
13. 17DD and 17D-213/77 yellow fever substrains trigger a balanced cytokine profile in primary vaccinated children.
Campi-Azevedo AC; de Araújo-Porto LP; Luiza-Silva M; Batista MA; Martins MA; Sathler-Avelar R; da Silveira-Lemos D; Camacho LA; de Menezes Martins R; de Lourdes de Sousa Maia M; Farias RH; da Silva Freire M; Galler R; Homma A; Ribeiro JG; Lemos JA; Auxiliadora-Martins M; Caldas IR; Elói-Santos SM; Teixeira-Carvalho A; Martins-Filho OA
PLoS One; 2012; 7(12):e49828. PubMed ID: 23251351
[TBL] [Abstract][Full Text] [Related]
14. Persistence of Neutralizing Antibody Responses Among Yellow Fever Virus 17D Vaccinees Living in a Nonendemic Setting.
Kareko BW; Booty BL; Nix CD; Lyski ZL; Slifka MK; Amanna IJ; Messer WB
J Infect Dis; 2020 Jun; 221(12):2018-2025. PubMed ID: 31545367
[TBL] [Abstract][Full Text] [Related]
15. 17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients.
Wieten RW; Goorhuis A; Jonker EFF; de Bree GJ; de Visser AW; van Genderen PJJ; Remmerswaal EBM; Ten Berge IJM; Visser LG; Grobusch MP; van Leeuwen EMM
J Infect; 2016 Jun; 72(6):713-722. PubMed ID: 27017899
[TBL] [Abstract][Full Text] [Related]
16. Yellow fever vaccination elicits broad functional CD4+ T cell responses that recognize structural and nonstructural proteins.
James EA; LaFond RE; Gates TJ; Mai DT; Malhotra U; Kwok WW
J Virol; 2013 Dec; 87(23):12794-804. PubMed ID: 24049183
[TBL] [Abstract][Full Text] [Related]
17. The 17D-204 Vaccine Strain-Induced Protection against Virulent Yellow Fever Virus Is Mediated by Humoral Immunity and CD4+ but not CD8+ T Cells.
Watson AM; Lam LK; Klimstra WB; Ryman KD
PLoS Pathog; 2016 Jul; 12(7):e1005786. PubMed ID: 27463517
[TBL] [Abstract][Full Text] [Related]
18. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection.
Reinhardt B; Jaspert R; Niedrig M; Kostner C; L'age-Stehr J
J Med Virol; 1998 Oct; 56(2):159-67. PubMed ID: 9746073
[TBL] [Abstract][Full Text] [Related]
19. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects.
Guy B; Nougarede N; Begue S; Sanchez V; Souag N; Carre M; Chambonneau L; Morrisson DN; Shaw D; Qiao M; Dumas R; Lang J; Forrat R
Vaccine; 2008 Oct; 26(45):5712-21. PubMed ID: 18762226
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of humoral immune response after yellow fever infection: an observational study on patients from the 2017-2018 sylvatic outbreak in Brazil.
Gonçalves AP; Almeida LT; Rezende IMd; Fradico JRB; Pereira LS; Ramalho DB; Pascoal Xavier MA; Calzavara Silva CE; Monath TP; LaBeaud AD; Drumond BP; Campi-Azevedo AC; Martins-Filho OA; Teixeira-Carvalho A; Alves PA;
Microbiol Spectr; 2024 May; 12(5):e0370323. PubMed ID: 38511952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
